RE:RE:RE:RE:RE:RE:RE:NSU P/E Ratio At 56 Times EarningsLongrider, you're proving my point. Development stage pharma companies aren't valued on earnings either. They are valued based on discounted future cash estimates with varying risk discounts. You are quite right though. Nsu might or might not have the goods, that's one of the reasons why resource stocks trade a large discounts to their "estimated ore in the ground." But earnings from bisha are not a proper way to evaluate the company because it doesn't take into account Timok at all and Timok's value far exceeds bisha. Ask yourself why on all the analysts reports, why do none of the them use P/e as a metric for valuing Nsu - or any other mid sized resource company.? Because it doesn't reflect the value of their assets at all . It's not my opinion, it's a fact